<DOC>
	<DOCNO>NCT01459887</DOCNO>
	<brief_summary>CD20 , protein express surface mature B cell , active many B-cell lymphoma express molecule Diffuse Large B Cell Lymphoma ( DLBCL ) , frequently occur subtype non-Hodgkin lymphoma . In clinical practice , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone combination chemotherapy ( CHOP ) still consider one standard treatment DLBCL . CMAB304 ( Retuxira ) , chimeric monoclonal antibody design targeted CD20 treatment lymphoma diseases . This trial aim observe safety efficacy CMAB304 , add CMAB304 CHOP chemotherapy regimen compare CHOP chemotherapy alone .</brief_summary>
	<brief_title>Study Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Treat Non-hodgkin 's Lymphoma</brief_title>
	<detailed_description>Rituximab , chimeric anti-CD20 monoclonal antibody , prove valuable treatment CD20-positive DLBCL . The combination rituximab CHOP show increase survival response rate , comparison CHOP alone . CMAB304 ( Retuxira ) , biosimilar rituximab , develop Shanghai CP Guojian Pharmaceutical Co. , Ltd . Previous Phase I study show CMAB304 well tolerate monotherapy pharmacokinetic data exhibit non-linear profile dose range 250 500 mg/m2 . In study , efficacy safety CMAB304 evaluate DLBCL patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Age 18 70 year , male female 2 . Previously untreated 3 . DLBCL patient CD20positive 4 . Lymphoma lesion Measured evaluate ; Spiral CT MR evaluation lesion must ≥ 1cm ; Measured clinical examination others must ≥ 2cm 5 . Normal blood test , adequate liver renal function ; 6 . ECOG score 0~2 7 . Life expectancy great 3 month 8 . No malignancy treatment history , except cure carcinoma situ cervix squamous cell basal cell skin cancer 9 . Signed ICF 1 . DLBCL transform lowgrade NHL type 2 . Primary central nervous system lymphoma , primary gastrointestinal DLBCL 3 . History foreign protein allergies 4 . Abnormal liver and/or renal function 5 . Suspected diagnosed central nervous system violation 6 . Serious infection organic diseases 7 . Heart disease , heart failure , heart block second degree , myocardial infarction occur within six month 8 . Breastfeeding pregnant 9 . Leukemia crisis bone marrow metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>untreated , CD20-positive</keyword>
</DOC>